Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nihon Rinsho. 1997 May;55(5):1149-54.

[Mechanism of acquired antiestrogen resistance and its management in breast cancer].

[Article in Japanese]

Author information

  • 1Department of Emergency and Critical Care Medicine, Gunma University School of Medicine.

Abstract

Although non-steroidal antiestrogen, tamoxifen(TAM), has been known to be useful for estrogen receptor(ER)-positive breast cancer, acquired tamoxifen resistance frequently occurs during the treatment. Several factors seem to be responsible for the resistance; decreased level of ER, mutation of ER, agonistic effect of TAM, ovarian steroidogenesis, altered metabolism of TAM, and increased expression level of antiestrogen binding sites. Withdrawal of TAM and second-line endocrine therapy might be effective on the tamoxifen resistant breast cancer which retains estrogen dependency. Otherwise, chemotherapy should be chosen for estrogen-independent breast cancer which has lost ER and fails to respond to other endocrine therapy. In this context, the menstrual status, serum level of estradiol, and steroid receptor status should be considered for the management of acquired antiestrogen resistance in breast cancer.

PMID:
9155167
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk